MAMichael J. Arnold

Michael J. Arnold

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Michael J. Arnold has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Perceptions of a Menthol Cigarette and Flavored Cigar Ban Among Black and White Adults Who Smoke Menthol Cigarettes, United States, 2024

    by Michael J. Arnold, Eleanor L.S. Leavens, Lisa Sanderson Cox, Alexandra Brown, Matthew S. Mayo, Nathaniel L. Baldwin, Thu A. Nguyen, Nicole L. Nollen

    Objectives: Menthol flavoring is a critical public health issue, but prior research has largely represented the voices of White adults who smoke menthol cigarettes, who represent a small subset of adults who smoke menthol cigarettes in the United States. This study compared perceptions of a hypothetical menthol cigarette or flavored cigar (MC/FC) ban among Black and White adults who smoke menthol cigarettes. Methods: Participants were a convenience sample of 2113 Black and 1087 White adults who smoke menthol cigarettes, collected through Amazon Mechanical Turk from July 2023 through January 2024. Participants reported opinions about an MC/FC ban, the likely public health outcomes, and a hypothetical impact of the ban on their smoking behavior. We used stepwise logistic regression to model factors associated with ban opposition or ambivalence. Results: More than one-third of adults who smoke menthol cigarettes supported an MC/FC ban (37.2% Black vs 34.5% White; P = .13), but Black (vs White) adults who smoke menthol cigarettes were more likely to endorse the public health benefits of a ban, as assessed via agreement with 5 statements of US Food and Drug Administration rationale (mean [SD] number of statements endorsed, 3.0 [1.7] vs 2.4 [1.8]; P < .001). Smoking more cigarettes per day, believing that menthol cigarettes are more addictive or harder to quit than nonmenthol cigarettes, and intending to continue using nicotine under a ban increased the odds of opposition or ambivalence to the ban. Conclusions: Targeted outreach to those who consume predominantly menthol products and those who do not intend to quit nicotine could increase support of an MC/FC ban among adults who smoke menthol cigarettes.

  • Open Access

    GLP-1 receptor agonist indications and prescriptions among adults who do and do not smoke

    by Eleanor L.S. Leavens, Michael J. Arnold, Nicole L. Nollen, Lisa Sanderson Cox, Kristy A. Brown, Edward F. Ellerbeck

    Background: Smoking and obesity are leading causes of preventable morbidity and mortality, often co-occurring and synergistically increasing risks for cardiovascular disease and diabetes. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are effective for managing type 2 diabetes, obesity, and cardiovascular disease, and emerging evidence suggests potential benefit for smoking cessation. However, the prevalence of GLP-1 RA indications and prescriptions among adults who smoke is unknown. Objective: To compare the frequency of GLP-1 RA indications and prescriptions among adults who do and do not smoke within a large Midwest health system. Methods: Electronic health record data identified adults (≥18 years) with outpatient primary care visits from September 2023–2024. Patients were categorized as current smokers or non-smokers. We assessed indications for GLP-1 RAs—type 2 diabetes, weight management (BMI ≥30 or 27– 29.9 with comorbidity), and secondary prevention of cardiovascular disease and examined prescription rates among those with at least one indication. Results: Of 59,981 patients, 4,843 (8.1%) were current smokers. Compared to non-smokers, adults who smoke were more likely to have an indication for GLP-1 RAs (66.1% vs. 62.6%; p p <0.001). This pattern was consistent across all indications. Conclusion: Adults who smoke more frequently meet clinical criteria for GLP-1 RAs yet are less likely to be prescribed these therapies. Enhancing access to GLP-1 RAs for individuals who smoke could address critical metabolic and smoking-related health challenges, particularly given their potential role in supporting smoking cessation.

  • Open Access

    Perceptions of a Menthol Cigarette and Flavored Cigar Ban in Black and White Adults in the United States who Smoke Menthol Cigarettes and Factors Associated with Ban Opposition or Ambivalence

    by Michael J. Arnold, Eleanor L.S. Leavens, Lisa Sanderson Cox, Alexandra Brown, Matthew S. Mayo, Nathaniel L. Baldwin, Thu A. Nguyen, Nicole L. Nollen

    Objectives Menthol flavoring is a critical public health issue, but prior work has largely represented the voices of White adults who smoke (AWS) menthol cigarettes who comprise a small subset of AWS menthol cigarettes in the US. This study compared perceptions of a hypothetical MC/FC ban among Black and White AWS menthol cigarettes. Methods Participants were a convenience sample of 2,113 Black and 1,087 White AWS menthol cigarettes collected through Amazon Mechanical Turk between July 2023 and January 2024. Participants reported opinions about a MC/FC ban, likely public health outcomes, and hypothetical impact of the ban on their smoking behavior. Stepwise logistic regression modeled factors associated with ban opposition/ambivalence. Results Over one-third of menthol cigarette users supported a MC/FC ban (Black, 37.2% vs White, 34.5%, p=.13], but Black AWS were more likely to endorse public health benefits of a ban assessed via agreement with 5 statements of FDA rationale [3.0 (SD=1.7) versus 2.4 (SD=1.8), p<.001]. Smoking more cigarettes per day, belief that menthol cigarettes are more addictive/harder to quit, and intent to continue using nicotine under a ban increased odd of opposition/ambivalence. Conclusions Compared to White AWS, Black AWS were more likely to believe that a MC/FC ban would benefit public health and showed no statistical difference in overall support for a ban. Targeted outreach to those who consume more menthol products and those who do not intend to quit nicotine could increase ban support among menthol users. What is the current understanding of this subject?Knowledge of the public’s perception of a MC/FC ban is largely informed by White menthol cigarette users. Given that Blacks represent the majority of AWS menthol cigarettes in the US, the paucity of data from Black voices engenders a critical gap in research used to inform health policy. What does this report add to the literature?Compared to White AWS, Black AWS were more likely to believe that a MC/FC ban would benefit public health and showed no statistical difference in overall support for a ban. To our knowledge, this study comprises the largest convenience sample of perceptions and perceived impact of a federal MC/FC product standard among Black AWS menthol cigarettes in the US and provides valuable evidence to inform policy action in these areas. What are the implications for public health practice?Findings support ongoing efforts to advance a MC/FC product standard and suggest that targeted outreach to those who consume more menthol products and those who do not intend to quit nicotine could increase ban support among menthol users.


  • Open Access

    Protocol from a randomized clinical trial of multiple pharmacotherapy adaptations based on treatment response in African Americans who smoke

    by Nicole L. Nollen, Lisa Sanderson Cox, Matthew S. Mayo, Edward F. Ellerbeck, Michael J. Arnold, Gary Salzman, Denton Shanks, Jennifer Woodward, K. Allen Greiner, Jasjit S. Ahluwalia


  • Harm Reduction Associated with Dual Use of Cigarettes and e-Cigarettes in Black and Latino Smokers: Secondary Analyses from a Randomized Controlled e-Cigarette Switching Trial

    by Michael J Arnold, Nicole L Nollen, Matthew S Mayo, Jasjit S Ahluwalia, Eleanor L Leavens, Guanlin Zhang, Myra Rice, Kim Pulvers

    Most adult cigarette smokers who use e-cigarettes are dual cigarette and e-cigarette (CC-EC) users, yet little is known about relative consumption of cigarettes to e-cigarettes and any associated harm reduction. Rate of substitution from cigarettes to e-cigarettes at week 6 and change in biomarkers of exposure and potential harm were examined among dual dual cigarette and e-cigarette users [64/114 (56%); 35 Black, 29 Latino] in an e-cigarette switching randomized trial. Dual users averaged 79% substitution of cigarettes for e-cigarettes at week 6, resulting in a reduction from baseline of 70.0 ± 54.1 cigarettes per week (p < .001). Total nicotine consumption remained stable (baseline: 1160.5 ± 1042.1 pg/mL of cotinine, week 6: 1312.5 ± 1725.9 pg/mL of cotinine, p = .47), while significant reductions were seen in the potent lung carcinogen 4-(methylnitrosamino)-1-(3-pyridul)-1-butanol (NNAL) (-55.9 ± 88.6 ng/ml, p < .001), carbon monoxide (-6.3 ± 8.6 ppm, p < .001), and self-reported respiratory symptoms (−3.3 ± 8.0, p = .002). No significant changes were found in blood pressure or spirometry. Greater substitution from cigarettes to e-cigarettes was associated with larger reductions in NNAL (r = −.29, p = .02). The predominant dual-use pattern was characterized by regular e-cigarette and intermittent cigarette use. Findings demonstrate the short-term harm reduction potential of this dual-use pattern in Black and Latino smokers and suggest that the greatest benefit, aside from cessation of both products, is achieved by higher substitution of e-cigarettes for cigarettes. Findings need confirmation in a larger sample with longer follow-up in dual users with greater variability in the rate of substitution. NCT03511001 Findings suggest short-term harm reduction potential of dual cigarette-e-cigarette use for Black and Latino smokers. Results also demonstrate the heterogeneity of dual-use, with the greatest harm reduction seen in dual users with higher rates of substitution from cigarettes to e-cigarettes. Study results should be confirmed in a full clinical trial with long-term follow-up to evaluate maintenance of dual-use patterns and associated harm reduction potential over time.